Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, w ...
Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based growth across geographies and improved margins, according to Zee Business Resea ...
